LENZ Therapeutics, Inc.
No enriched coverage for $LENZ in the last 7 days.
No SEC Form 4 filings for $LENZ in the last 30 days.
See all $LENZ insider activity →LENZ Therapeutics' average stock price target was reduced from $25 to $22 by analysts, with a range of $7 to $60. This implies a 504% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 7 analysts.
LENZ Therapeutics reported Q2 2026 revenue of $5.5M, with product revenue up 9% QoQ. Prescription growth surged 45% in July, driven by telehealth and advertising. Net loss was $31.9M, with $220M in cash reserves. The company highlighted strong patient persistence and global partnerships.
Lenz Therapeutics reported Q2 2026 revenue of $5.5 million, including $3.8 million in license revenue tied to regulatory and sublicense milestones in Canada and Greater China. Management said July prescriptions rose 45% month over month after a national TV campaign and a telehealth access pathway. The company expects direct gross margins near 90% over time and continued international expansion.
Recent LENZ coverage spans financial news, earnings and corporate actions.
LENZ Therapeutics' average stock price target was reduced from $25 to $22 by analysts, with a range of $7 to $60. This implies a 504% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 7 analysts.
LENZ posted modest revenue growth but a sizable net loss, indicating heavy marketing spend and cash runway.
Telehealth plus TV-driven demand appears to be improving conversion and persistence, but Q3 will determine which commercial levers deliver the best ROI.
The stock move is driven by a sizable Q2 revenue beat and improving commercial traction (VIZZ packs and prescriptions), plus a less-bullish but still positive Citi stance.
The 8-K provides fresh commercial traction metrics (packs, refill behavior, prescriber uptake) plus cash and expense updates, shaping near-term sentiment and risk.
AlphAI scores every news story that mentions LENZ with an AI model for sentiment and relevance, and aggregates insider trades from LENZ Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LENZ Therapeutics' average stock price target was reduced from $25 to $22 by analysts, with a range of $7 to $60. This implies a 504% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 7 analysts.
1 min readLENZ Therapeutics reported Q2 2026 revenue of $5.5M, with product revenue up 9% QoQ. Prescription growth surged 45% in July, driven by telehealth and advertising. Net loss was $31.9M, with $220M in cash reserves. The company highlighted strong patient persistence and global partnerships.
3 min readLenz Therapeutics reported Q2 2026 revenue of $5.5 million, including $3.8 million in license revenue tied to regulatory and sublicense milestones in Canada and Greater China. Management said July prescriptions rose 45% month over month after a national TV campaign and a telehealth access pathway. The company expects direct gross margins near 90% over time and continued international expansion.
7 min readLENZ Therapeutics shares rose about 7.7% pre-open after the company reported Q2 2026 results Aug. 11. Revenue was $5.5M vs about $2.5M expected. EPS loss was $1.02 vs $1.07 expected. Product revenue was $1.7M and license revenue $3.8M. VIZZ prescriptions rose 45% in July. Citi reiterated Buy but cut its target to $10 from $20.
4 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy
6 min readLENZ Therapeutics (Nasdaq: LENZ) said VIZZ (aceclidine ophthalmic solution) 1.44% is now available via a telehealth platform at VIZZ.com, adding online eligibility evaluation by licensed eye care providers, e-pharmacy fulfillment, and home delivery. LENZ plans to promote the channel with a national TV campaign featuring Sarah Jessica Parker.
4 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. lenz-20260630 FALSE 0001815776 Solana Beach California 0001815776 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics, Inc. (LENZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. lenz-20260612 FALSE 0001815776 Solana Beach California 0001815776 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of e
2 min readLENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year's revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.
3 min readWall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a "hold" to a "sell" rating. This follows a similar downgrade by Weiss Ratings, although the consensus among analysts still rates the stock as a "Moderate Buy" with an average target price of $56.40. The article also details the company's stock performance, institutional investor holdings, and company profile.
3 min read
